Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telatinib - Bayer/Eddingpharm

Drug Profile

Telatinib - Bayer/Eddingpharm

Alternative Names: BAY-57-9352; EOC-315; Telatinib mesylate

Latest Information Update: 08 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer ACT Biotech; Eddingpharm
  • Class Antineoplastics; Furans; Pyridazines; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer
  • Phase I Solid tumours
  • No development reported Colorectal cancer

Most Recent Events

  • 31 May 2019 Adverse events and pharmacokinetics data from a phase I trial in Solid tumours presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 25 Jan 2019 Phase-II clinical trials in Gastric cancer (Combination therapy, First-line therapy, Late-stage disease, In adults, In the elderly) in China (PO) (NCT03817411)
  • 25 Jan 2019 EddingPharm Oncology plans a phase II trial for Gastric cancer (Combination therapy, Late-stage disease) (NCT03817411)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top